← Back to Search

Tetracycline Antibiotic

Minocycline for Kidney disease

N/A
Waitlist Available
Led By Sharon G Adler, MD
Research Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 mos
Awards & highlights
All Individual Drugs Already Approved

Summary

This trial is testing minocycline, an antibiotic, to see if it can safely help people with Type 2 diabetes who have kidney disease. Current treatments can cause serious side effects, so a safer option is needed. Minocycline has shown promise in animal studies by protecting kidney cells from damage.

Eligible Conditions
  • Kidney disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 mos
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 mos for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Other study objectives
Safety

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MinocyclineExperimental Treatment1 Intervention
Minocycline 100 mg po bid for 6 months
Group II: PlaceboPlacebo Group1 Intervention
Placebo one tablet po bid

Find a Location

Who is running the clinical trial?

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterLead Sponsor
104 Previous Clinical Trials
46,553 Total Patients Enrolled
Sharon G Adler, MDPrincipal InvestigatorLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
~2 spots leftby Nov 2025